Amatuximab (MORab-009) is a chimeric humanized IgG1/k monoclonal antibody targeting mesothelin (MSLN), a glycosylphosphatidylinositol (GPI)-anchored membrane glycoprotein expressed on limited normal adult tissues such as mesothelium. It binds to mesothelin, a protein produced by certain cancer cells, and inhibits cell division.